In young adults with psoriasis, substantial quality of life (QOL) impairments were found, according to a recent study. Furthermore, female patients, patients with high body mass index (BMI), or long disease duration in particular tended to experience more difficulties. Researchers conducted an explorative, cross-sectional study in patients with psoriasis aged 18–30 years (n=75 [22 males, 53 females]). Individuals completed a set of questionnaires regarding their health status, achievement of developmental milestones, and work productivity. They found:
- Median Psoriasis Activity and Severity Index (PASI) and body surface area (BSA), respectively, were 4.4 [4.9] and 4.5 [8.4].
- Young adults experienced feelings of embarrassment, impairments in physical health and work productivity, and difficulties in social development.
- Patients with more severe psoriasis, longer disease duration, higher BMI, female patients, and patients closer to their 30s tended to be more affected.
Bronckers IMG, van Geel MJ, van de Kerkhof PCM, de Jong EMGJ, Seyger MMB. A cross-sectional study in young adults with psoriasis: Potential determining factors in quality of life, life course and work productivity. [Published online ahead of print September 7, 2018]. J Dermatolog Treat. doi:10.1080/09546634.2018.1506077.
This Week's Must Reads
Dermatomyositis, Negative ANA, and Malignancy Risk, J Am Acad Dermatol; ePub 2018 Nov 17; Hoesly, et al
Head/Neck Melanomas Have High Local Recurrence Risk, J Am Acad Dermatol; ePub 2018 Nov 17; Fix, et al
DOT Laser Offers Low Incidence of Adverse Effects, J Drugs Dermatol; 2018 Nov; Sarnoff, Gotkin, et al
Frontal Fibrosing Alopecia and Severity Factors , Dermatology (Karger); ePub 2018 Nov 22; Mervis, et al
Unsafe Neighborhoods Linked with Higher AD Risk, Ann Allergy Asthma Immunol; ePub 2018 Oct 26; McKenzie, et al
Must Reads in Psoriasis
Genetic Architecture of Psoriasis Explored , J Investig Dermatol Proc; 2018 Dec; Elder
Association Found Between HS and Psoriasis, J Am Acad Dermatol; ePub 2018 Nov 28; Kridin, et al
Ixekizumab Provides Rapid Improvement of Itch, Dermatolog Ther (Heidelb); ePub 2018 Dec; Yosipovitch, et al
Role of IL-17 in Psoriasis Pathogenesis Examined, Clin Rev Allerg Immunol; 2018 Dec; Blauvelt, et al
Ixekizumab: A Safe, Effective Psoriasis Treatment , J Cutan Med Surg; ePub 2018 Nov 18; Georgakopoulos, et al